Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTNS vs PTNS + Fesoterodine for Overactive Bladder
NCT01605617Phase 4Terminated
- Sponsor
- Mayo Clinic
- Start
- Jun 2012
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fesoterodine in overactive bladder (OAB) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Number of Urinary Voids Per 24 Hours at 12 weeks. Started Jun 2012; status: terminated.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01605617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605617.